Gut Microbes Prime Regulatory B Cells That Shape Cancer Immunotherapy Outcomes

Checkpoint inhibitors have transformed the treatment of advanced cancers, yet only a minority of patients derive lasting benefit, and many develop immune-related adverse events that force treatment to stop. A review published in Cancer Immunology, Immunotherapy by Akshay J. Patel and Gary W. Middleton of the University of Birmingham argues that a long-underappreciated arm of the immune system, the regulatory B cell, sits at the intersection of these two clinical problems and that its behaviour is orchestrated, in large part, by the trillions of microbes inhabiting the gut. The synthesis, published open access on 2 October 2026, weaves together evidence from autoimmune models, cancer studies and early clinical trials to propose that the microbiome’s influence on immunotherapy may run through B cells programmed to suppress immunity.

Regulatory B cells, or Bregs, are a subset of B lymphocytes defined less by a single surface marker than by what they secrete. Their signature products are the immunosuppressive cytokines interleukin-10, interleukin-35 and transforming growth factor beta. Through these molecules, Bregs restrain effector immune responses, reining in the very CD8-positive T cells that checkpoint blockade drugs such as nivolumab and ipilimumab are designed to unleash against tumours. This creates what the authors describe as a fundamental tension: the same interleukin-10 programme that protects patients from the collateral inflammation of immunotherapy also dampens the tumour-directed cytotoxic response that the therapy depends upon. Understanding how Bregs are generated, where they accumulate and what feeds their suppressive machinery therefore has direct implications for predicting and manipulating responses to checkpoint inhibitors.

The review anchors the microbiome-Breg relationship in two mechanistic axes. The first is a cytokine-driven pathway. Gut commensal bacteria stimulate myeloid cells to produce interleukin-1 beta and interleukin-6, which act on matching receptors on B cells. This signalling drives the differentiation of B cells into interleukin-10-competent regulatory cells in the spleen and mesenteric lymph nodes, the lymphoid tissues that drain the intestine. In other words, the microbial ecology of the gut supplies the inflammatory context that teaches B cells to become suppressive. The second axis is metabolic rather than cytokinic: microbially derived short-chain fatty acids, principally butyrate, amplify aryl hydrocarbon receptor signalling within Bregs. Notably, this route increases the suppressive capacity of individual Bregs rather than expanding their numbers, meaning the gut can tune the potency of the regulatory compartment without changing its size.

To connect intestinal biology with tumour immunology, the authors adopt the gut-lung axis as their organising framework. This concept, well established in respiratory research, holds that microbial products and immune cells primed in the gut can influence immune responses in the lung. Because lung cancer, particularly non-small cell lung cancer, is one of the flagship indications for checkpoint blockade, the framework matters clinically. The review is careful, however, to separate evidence generated directly in cancer models from data drawn from autoimmune and inflammatory disease research, an important distinction because Breg biology studied in lupus or colitis may not translate cleanly to the tumour microenvironment.

Four testable gaps emerge from the synthesis, each of which could shape the next decade of research. First, it remains unknown whether gut-induced Bregs actually traffic to lung tumours or their draining lymph nodes, a question that could be addressed with lineage tracing and parabiosis-style experiments. Second, the authors ask whether lung-resident commensal bacteria can generate lung-resident Bregs, mirroring what has been described in the pancreas, where local commensals drive epithelial cells to produce interleukin-1 beta and thereby shape the local immune landscape. Third, they highlight the possibility that microbiota-selected B cell receptor clonotypes feed the Breg pool, implying that the antigen specificity of regulatory B cells is not random but curated by the microbial environment. Fourth, and most relevant to human disease, the metabolic programme that sustains Bregs within human tumours has not been defined, leaving a gap between mouse mechanistics and clinical application.

The clinical stakes are illustrated by striking results from microbiome-targeted interventions. Faecal microbiota transplantation from healthy donors, performed before checkpoint blockade, produced objective response rates of 80 percent in first-line non-small cell lung cancer and 75 percent in melanoma in the studies reviewed. These figures far exceed the response rates typically achieved with checkpoint inhibitors alone in these settings, suggesting that reshaping the microbial environment can meaningfully reprogramme antitumour immunity. Separately, the live biotherapeutic CBM588, a strain of Clostridium beijerinckii, added to nivolumab and ipilimumab in renal cell carcinoma yielded a progression-free survival hazard ratio of 0.15, with a 95 percent confidence interval of 0.05 to 0.47, indicating a substantial reduction in the risk of progression or death compared with checkpoint blockade alone.

How might these dramatic effects connect to Bregs? The review’s mechanistic framework offers a plausible chain of causation. Transplanted or probiotic microbes alter the cytokine and metabolite milieu of the gut, changing the signals that drive Breg differentiation and potency. A gut environment rich in butyrate-producing organisms could amplify aryl hydrocarbon receptor signalling in Bregs, strengthening their suppressive output, while a microbiome that skews myeloid interleukin-1 beta and interleukin-6 production could expand the interleukin-10-competent pool. Depending on the balance, this could either blunt the antitumour T cell response that checkpoint blockade seeks to unleash or, conversely, restrain the autoimmune inflammation that causes immune-related adverse events. The dual role of the interleukin-10 programme means that any intervention shifting Breg behaviour will have consequences on both sides of the therapeutic ledger.

The authors are explicit that risk accompanies opportunity. Donor screening excludes most candidates for faecal microbiota transplantation, reflecting the stringent filtering required before a donor sample is considered safe. Drug-resistant Escherichia coli bacteraemia has followed FMT in documented cases, a sobering reminder that live microbial products can cause invasive infection. Transmission of procarcinogenic bacteria also remains possible, raising the theoretical concern that a transplant intended to boost immunotherapy could inadvertently introduce organisms that promote carcinogenesis. These risks are specific rather than generic, and they underscore why the field has moved toward defined live biotherapeutics such as CBM588, which offer a more controllable microbial intervention than whole-stool transfer.

The review also carries implications for managing immune-related adverse events, the colitis, pneumonitis, hepatitis and other inflammatory toxicities that complicate checkpoint blockade. If Bregs induced by gut commensals limit these toxicities, then patients whose microbiomes fail to induce robust Breg responses might be disproportionately vulnerable to severe irAEs, while those with butyrate-rich, Breg-supporting microbial communities might tolerate therapy better but respond less well to it. Stratifying patients by microbial and Breg signatures before treatment could therefore identify who needs closer monitoring for toxicity and who might benefit from interventions that temporarily restrain regulatory circuits to enhance antitumour immunity.

Patel and Middleton’s synthesis ultimately reframes the microbiome’s role in cancer immunotherapy as a B cell story waiting to be told. Much of the existing literature has focused on T cells, dendritic cells and myeloid populations when explaining why gut microbes modulate checkpoint inhibitor efficacy. By centring regulatory B cells and their dependence on microbial cytokine and metabolite cues, the review identifies a concrete, mechanistically grounded cell type through which diet, probiotics, FMT and even antibiotics might be rationally deployed. The four gaps the authors define, from Breg trafficking to the lung tumour microenvironment to the metabolic sustenance of human tumour Bregs, provide a research agenda that is deliberately testable. As microbiome-targeted therapeutics move from small trials toward standard oncology practice, understanding whether the Breg arm of immunity is the conduit through which microbes exert their clinical effects will be essential to harnessing the benefit while containing the risk.

Subject of Research: How the microbiome regulates B cells to influence checkpoint blockade immunotherapy in cancer

Article Title: Regulatory B cells and the microbiome: implications for checkpoint blockade therapy in cancer

Article References: Patel, A. J., & Middleton, G. W. (2026). Regulatory B cells and the microbiome: implications for checkpoint blockade therapy in cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04563-0

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04563-0

Keywords: regulatory B cells, microbiome, checkpoint blockade, cancer immunotherapy, gut-lung axis, interleukin-10, short-chain fatty acids, butyrate, faecal microbiota transplantation, immune-related adverse events, non-small cell lung cancer, tumour immunology